Caristo Diagnostics Accelerates Growth and Innovation in 2024, Leading the Way in Heart Disease Prevention and Management
Driven by groundbreaking technology, expanding clinical adoption, record client growth, and key strategic partnerships, Caristo is reshaping the future of cardiovascular care
Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, is celebrating exceptional growth and performance in 2024. This success is driven by strong validation of its CaRi-Heart® technology, an expanding client base, strategic partnerships, and the launch of its first U.S. office.
As the global burden of heart attacks and strokes continues to rise, Caristo remains at the forefront of improving early diagnosis and intervention.
In 2024, the company welcomed a more than 2x increase in clinical adoption of its flagship CaRi-Heart AI-powered technology for detecting coronary inflammation and plaque among its existing clients, including:
- National Health Service (NHS)
- HCA UK (Caristo’s strategic reference partner in the UK)
- One Welbeck
- Cleveland Clinic UK
- Mayo Clinic UK
The company also recorded numerous new Caristo clients in 2024, including renowned hospitals, clinics, and cardiologists across the UK and EU. Notable new UK adopters in 2024 included:
- Cromwell Hospital (London, UK), a leading private medical institution
- Hooke London, a longevity clinic focused on health span optimization
- myGP Clinic, a patient-centered primary care group with multiple UK locations
In the EU, clinical adoption of Caristo’s technology doubled year-over-year and is expected to grow further with its introduction at Groupe Prive Hospitalier Ambroise Paré Hartmann, a 400-bed provider of cardiology care in Neuilly-sur-Seine, France. The hospital serves nearly 50,000 patients annually, with its cardiac imaging team led by renowned cardiologist Dr. Laurent Macron.
Caristo’s impressive traction in 2024 also led to a significant year-over-year revenue increase and marked the company’s first partnerships with major global pharmaceutical and biotech companies.
These collaborations included:
- The use of CaRi-Heart technology to monitor results from a Phase 2a pilot, placebo-controlled, randomised clinical trial of Orticumab, a new drug from Abcentra that combats coronary inflammation in patients with psoriasis. The trial’s promising results were presented at the 2024 American College of Cardiology (ACC) Annual Scientific Sessions and concurrently published in Cardiovascular Research
- The use of Caristo as the core imaging lab supporting clinical trial operations in eight countries and over 50 clinical sites for a major phase 2 pharmaceutical customer
Other major clinical and business highlights from Caristo’s transformative year include:
- Opening of the company’s first US office, in Stamford, Conn., with the goal of making CaRi-Heart technology accessible to U.S. patients in the region, post FDA clearance
- Completion of over 1,000 paid analyses for the National Health Service (NHS), delivering high clinician and patient satisfaction through CaRi-Heart technology’s visualisation of coronary inflammation and plaque
- Publishing a landmark multi-center cohort study in The Lancet, validating CaRi-Heart technology’s prognostic value in detecting coronary inflammation and predicting cardiac events
- A peer-reviewed study in the European Heart Journal, demonstrating CaRi-Heart’s potential to provide cost-effective cardiac care within the UK’s NHS, with the possibility of reducing overall cardiac deaths by 12%.
Caristo’s CaRi-Heart Technology received great recognition from prestigious award platforms and leading media outlets:
- Named among Newsweek’s World’s Best Digital Health Companies for 2024
- Recognised a finalist for British Heart Foundation’s ‘Research Project of the Year’ Award
- Won the Digital Health Hub Foundation’s Digital Health Award and the Fierce Healthcare Innovation Award
- Highlighted as a major 2024 breakthrough by Dr Eric Topol, MD, a renowned cardiologist, in the popular Apple podcast ‘Plain English with Derek Thompson’
- Nvidia’s AI podcast featuring Prof. Keith Channon, Co-founder and Chief Medical Officer at Caristo Diagnostics, ranked in the five most-loved episodes of 2024
- CaRi-Heart technology featured in The BBC, on their prime-time TV program
“We are proud of our progress in 2024, which reflects the growing recognition of CaRi-Heart as a breakthrough technology in cardiovascular health,” said Frank Cheng, CEO of Caristo Diagnostics. “By unveiling hidden coronary inflammation and plaque within routine cardiac CT scans, CaRi-Heart empowers physicians and patients to take early action. This proactive approach improves clinical outcomes while delivering significant value for healthcare systems and patients alike.”
###
